Comparative Pharmacology
Head-to-head clinical analysis: HERCEPTIN versus HERCESSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HERCEPTIN versus HERCESSI.
HERCEPTIN vs HERCESSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2). It inhibits HER2-mediated signaling, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor cell proliferation.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It inhibits the proliferation of human tumor cells that overexpress HER2, and mediates antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing cancer cells.
Loading dose of 8 mg/kg IV over 90 minutes, followed by maintenance dose of 6 mg/kg IV over 30-90 minutes every 3 weeks. Alternatively, 4 mg/kg IV loading over 90 minutes, then 2 mg/kg IV over 30 minutes weekly.
10 mg subcutaneously daily for 21 consecutive days, followed by 7 days off therapy in 28-day cycles.
None Documented
None Documented
The terminal elimination half-life is approximately 28–38 days (mean 28.5 days). This long half-life allows for every-3-week dosing (loading dose 8 mg/kg, then 6 mg/kg q3w).
Terminal elimination half-life is 2.5–3.5 hours (mean ~3 hours) in patients with normal renal function; prolonged to 6–12 hours in moderate renal impairment and up to 20 hours in severe impairment.
Trastuzumab is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<20% of an administered dose is excreted in urine, likely as small peptides). Biliary/fecal excretion is not a major route; metabolic degradation yields amino acids.
Primarily excreted unchanged in urine via glomerular filtration and active tubular secretion; ~90% of dose recovered in urine as parent drug, ~5% in feces.
Category C
Category C
HER2 Inhibitor
HER2 Inhibitor